Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 5/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952709 | 0.96 | EDNRA (0.39) | ATMGSK3AGSK3BTSPOCFD | |
| SCHEMBL3958837 | 0.94 | EDNRB (0.38) | ATMGSK3AGSK3BTSPOEDNRB | |
| SCHEMBL3950085 | 0.93 | ATM (0.35) | ATMGSK3AGSK3BTSPOCFD | |
| SCHEMBL3950076 | 0.91 | CFD (0.41) | ATMGSK3AGSK3BTSPOCFD | |
| SCHEMBL3955748 | 0.91 | HTR3A (0.38) | ATMGSK3AGSK3BCFDHTR3A | |
| SCHEMBL3949945 | 0.90 | KDM4E (0.40) | ATMGSK3AGSK3BTSPOKDM4E | |
| SCHEMBL4784303 | 0.90 | TSPO (0.39) | ATMGSK3AGSK3BTSPOHTR3A | |
| SCHEMBL4783461 | 0.89 | TSPO (0.38) | ATMGSK3AGSK3BTSPOHTR3A | |
| SCHEMBL3951567 | 0.88 | HTR3A (0.37) | ATMTSPOCFDHTR3AKDM4E | |
| SCHEMBL3953798 | 0.88 | CFD (0.39) | ATMGSK3AGSK3BTSPOCFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771170-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080032951-A1 | Ophthalmic Compositions For Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-02-07 | — | — | US | claimed |
| EP-1771170-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006020003-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-7563816-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1771170-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080032951-A1 | Ophthalmic Compositions For Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-02-07 | — | — | US | disclosed |
| EP-1771170-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006020003-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032951-A1 | Ophthalmic Compositions For Treating Ocular Hypertension | KCNH2, KCNN1, KCNH3 | ATM 4474/4885GSK3A 1780/4885GSK3B 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.